2.2 Million Gut Cells Reveal the Genes Behind IBD

If you or someone you love has Crohn's disease or ulcerative colitis, you already know the frustrating part: doctors can treat the inflammation, but nobody can tell you exactly why your immune system turned on your gut in the first place. A new study gets closer to an answer by looking at the problem cell by cell, literally.

Key Takeaways

• Researchers built the largest single-cell map of gut and blood tissue in inflammatory bowel disease (IBD) to date, covering nearly 2.2 million cells from 421 people, and used it to trace genetic risk to specific genes acting in specific cell types.
• The team pinned down candidate disease-driving genes for more than half of the 321 known IBD genetic risk locations, including dozens never linked to a gene before.
• Two mechanisms stood out: misfiring immune signaling in dendritic cells (a type of immune cell that helps direct immune responses) and impaired renewal of the gut's stem cells, both pointing to concrete biological failure points, not just statistical associations.
• This is a genetic mapping study, not a treatment trial. It tells researchers where to look for new drugs, not what to take or change today.

Single-cell atlas links IBD risk genes to the cells where they act

Researchers at the Wellcome Sanger Institute and Cambridge University Hospitals, working with Open Targets, sequenced gene activity in nearly 2.2 million individual cells taken from gut biopsies and blood samples of 421 people, 125 of whom had Crohn's disease. Rather than asking which genes are broadly linked to IBD, they asked a more precise question: in which specific type of cell, out of dozens found in the gut, does each risk gene actually switch on or off? The project, which the team calls IBDverse, is the largest single-cell genetic map built for IBD so far, and it was published in Nature.

What this means for the roughly 5 million people living with IBD

Crohn's disease and ulcerative colitis together are estimated to affect close to 3 million people in the United States and millions more worldwide, and genome-wide studies have flagged hundreds of stretches of DNA linked to IBD risk without explaining what most of them actually do. That gap has been a real obstacle: drug targets backed by solid human genetic evidence are far more likely to succeed in clinical trials than targets picked another way. By tying genetic risk to specific cell types, this study gives drug developers a much sharper starting point than a generic "immune-related" gene list, and it helps explain why IBD can look and behave differently from one patient to another.

Why single-cell resolution succeeded where older methods stalled

The key methodological move was resolution. Earlier genetic mapping efforts typically analyzed whole tissue samples or broad groups of cells at once, which tends to wash out effects that only happen in one specific, often rare, cell type. This team instead mapped gene-regulating genetic variants, called eQTLs (expression quantitative trait loci, meaning DNA changes that raise or lower how active a nearby gene is), separately across 86 distinct cell types identified from gut and blood samples. The payoff was substantial: variants detected only at this fine-grained, single-cell-type level were more than 3.5 times more likely to line up with known IBD genetic risk regions than variants detected using traditional whole-tissue analysis. Genetic effects specific to a single cell type, in other words, were far more informative about disease risk than effects shared broadly across the whole tissue.

Two failure points: misdirected immune signaling and stalled gut repair

Using this fine-grained map, the researchers nominated candidate disease-driving genes for more than half of the 321 known IBD risk regions, including 74 where no gene had ever been proposed before. Two biological patterns dominated the results. The first centers on dendritic cells, immune cells that help the gut decide what to tolerate and what to attack. Genes including MAML2, ZMIZ1, and PSEN2 all showed altered activity in dendritic cells tied to disruption of Notch signaling (a cell-to-cell communication pathway that helps immune cells decide how to respond), suggesting that dialing down Notch activity in these cells may itself protect the gut from inflammation, and dialing it up may add to risk. The second pattern centers on the gut's epithelial stem cells, the cells that continuously rebuild the intestinal lining. Genes such as MYC, RASGRP1, and LPIN3, all tied to Wnt signaling (a pathway that governs cell renewal and division), showed altered activity in these stem cells, pointing to impaired barrier repair as a second, largely independent route into disease alongside immune dysfunction.

What this could mean for patients down the line

For someone currently managing IBD, this study does not change anything about today's treatment plan, and it is not a reason to ask about a new drug yet. What it does offer is a preview of where treatment research is headed. The team found that two genes already targeted by existing IBD drugs, ITGA4 (the target of vedolizumab) and JAK2 (the target of tofacitinib), showed exactly the pattern of genetic risk the theory would predict, which is reassuring validation that the overall approach works. More striking, they also flagged a kinase gene called PRKCB, whose inhibitors are already being tested in early-phase IBD clinical trials for unrelated reasons, and found that a drug already on the market for diabetes, metformin, acts on a gene, NDUFAF1, that showed the same UC-risk pattern in gut lining cells, a finding the authors think may help explain metformin's well-known gastrointestinal side effects. Anyone curious about a specific drug's mechanism should raise it directly with their gastroenterologist rather than drawing conclusions from a genetics paper.

The gap between genetic correlation and proof

The biggest caveat is built into the method itself. This study identifies genes whose activity statistically lines up, or colocalizes, with genetic risk for IBD in a particular cell type. That is strong circumstantial evidence, but it is not the same as proving a gene causes disease. The authors are explicit that real proof requires experimentally switching these genes off in the relevant cell types and confirming that inflammation follows, work that has not been done yet for the vast majority of the genes on this list. There is also a coverage limit: more than half of the cell types studied had fewer than 100 cells per person, which limits how confidently rare cell populations could be analyzed, meaning some real effects were likely missed rather than ruled out.

What comes next for IBD genetics research

The researchers describe IBDverse as a framework, not a finished answer, and expect the next wave of single-cell studies, larger and covering more diseased tissue, to fill in more of the roughly 140 IBD risk regions that still have no identified gene. They also point to newer statistical methods that could pull apart multiple overlapping genetic signals at the same risk region, something the current analysis was not built to do. No timeline was given for turning any of these candidate genes into an actual drug target; that stage, if it happens, would take years of additional laboratory and clinical work.

Common Questions

Does this study prove what causes IBD? No. It identifies genes whose activity in specific cell types statistically correlates with IBD genetic risk. The authors themselves say proving causation requires follow-up experiments that switch these genes off directly, which has not yet been done for most of the genes identified.

Is the gut microbiome involved in these findings? Not directly. This study is about human genetics and gene activity in gut and immune cells, not gut bacteria. The two mechanisms it points to, immune signaling in dendritic cells and stem cell renewal in the gut lining, are both processes known to interact heavily with the microbiome in other research, but this particular study did not measure microbial data.

Should I ask my doctor about metformin or PRKCB inhibitors for IBD? Not based on this study. Metformin is not an approved IBD treatment, and PRKCB inhibitors are still in early-phase trials. The study flags these as leads for future research and as a possible explanation for a known side effect, not as an established therapy.

Why did this study focus on Crohn's disease patients specifically? The 125 IBD patients in the study all had a history of Crohn's disease affecting the ileum, and biopsies were taken from that site. The genetic risk regions analyzed cover both Crohn's disease and ulcerative colitis, since the two conditions share substantial genetic overlap, but the diseased tissue samples themselves came from Crohn's patients.

References

1. Tobi Alegbe, Bradley T. Harris, Laura Fachal, et al. (2026). Cell-type-resolved genetic variation shapes inflammatory bowel disease risk. Nature. https://doi.org/10.1038/s41586-026-10627-z
2. IBD Facts and Stats (CDC). cdc.gov. https://www.cdc.gov/inflammatory-bowel-disease/php/facts-stats/index.html